☆ 4.7 Article Proceedings Paper

Relationship Between Breast and Axillary Pathologic Complete Response in Women Receiving Neoadjuvant Chemotherapy for Breast Cancer

ANNALS OF SURGICAL ONCOLOGY (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03

Joerg Heil et al.

Summary: This study evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to diagnose a pathologic complete response in the breast. The results showed a higher false-negative rate than expected, suggesting the need for improvements in procedure and patient selection before considering omitting breast surgery.

ANNALS OF SURGERY (2022)

添加到收藏夹

Article Oncology

Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Amparo Garcia-Tejedor et al.

Summary: Among patients with HER2-positive and triple-negative breast cancer staged as cN2 or with a high axillary burden before NACT, a sentinel lymph node biopsy after NACT could be recommended based on clinical and radiological responses. The study found that molecular surrogate subtype, Ki-67 expression, and responses to NACT were independent factors associated with achieving axillary pathologic complete response (ypN0). The distant disease-free survival rate was higher for patients with ypN0 compared to ypN+ after NACT.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study

Ariane A. van Loevezijn et al.

Summary: The study found that ultrasound-guided core biopsies are not accurate enough to identify breast pCR in patients with good response on MRI after neoadjuvant systemic therapy. Therefore, breast surgery cannot be safely omitted based solely on the results of core biopsies in these patients.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

The Role of Oncotype DX(R) Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer

Jaime A. Pardo et al.

Summary: This study found that Oncotype DX(R) RS can serve as an independent predictor for axillary pathologic complete response in ER +/HER2 - breast cancer patients receiving neoadjuvant chemotherapy. A greater proportion of patients with a high RS achieved axillary pCR, supporting the use of Oncotype DX(R) as a tool to improve clinical decision making in axillary management.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer

Roberto A. Leon-Ferre et al.

Summary: Neoadjuvant chemotherapy has become the preferred approach for most HER2-positive and triple-negative breast cancers, with initial motivations being to decrease surgical extent and advance drug development, recent trials have shown survival advantages from escalating systemic treatment in patients with residual disease.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer

Hank Schmidt et al.

Summary: With advancements in medical imaging and neoadjuvant chemotherapy, higher rates of pathologic complete response are being achieved in patients with invasive breast cancer, raising questions about the necessity of surgery and axillary lymph node dissection. Despite achieving pathologic complete response in the breast, some patients still have residual disease in the axillary lymph nodes. Further research is needed to select patients who may be able to avoid breast and axillary surgery after neoadjuvant chemotherapy treatments.

BREAST JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy A Nonrandomized Controlled Trial

Elizabeth J. Sutton et al.

Summary: The study found that the accuracy of MRI-guided biopsy in diagnosing post-NAC pCR approaches that of reference-standard surgical resection, indicating it may be a viable alternative for this population after NAC and further investigation is warranted.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Surgery

Treatment response correlation between primary tumor and axillary lymph nodes after neoadjuvant therapy in breast cancer: a retrospective study based on real-world data

Yu Wang et al.

Summary: The study identified factors influencing breast pathological response and axillary pathological response, with regional lymph node classification being a key factor for axillary response. Patients achieving pCR in the breast were likely to have pCR in the axilla, particularly in specific cases. However, certain patients were unlikely to achieve pCR in both the primary tumor and axillary lymph nodes.

GLAND SURGERY (2021)

添加到收藏夹

Article Oncology

Axillary response rates to neoadjuvant chemotherapy in breast cancer patients with advanced nodal disease

Neha Goel et al.

Summary: The study found that the majority of breast cancer patients with clinical N2-3 disease still had residual nodal disease after surgery, but 60.0% of patients with a complete clinical response also achieved a pathologic complete response.

JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Review Surgery

Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease A Systematic Review and Meta-analysis

Sanaz Samiei et al.

Summary: This study analyzed 33 unique studies with 57,531 patients to determine the axillary pathologic complete response (pCR) rates for different breast cancer subtypes in patients with initially clinically node-positive disease. The highest axillary pCR rate was associated with the HR-negative/ERBB2-positive subtype at 60%, followed by other subtypes in decreasing order. These findings can assist in estimating axillary treatment response and selecting appropriate procedures for patients in the neoadjuvant setting.

JAMA SURGERY (2021)

添加到收藏夹

Article Oncology

Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery

Jin Hong et al.

Summary: The study found that in breast cancer patients, ypN status in patients achieving breast pCR was significantly associated with clinical stage and molecular subtype. Patients with cT1-2N0 and HER2-positive disease who achieved breast pCR had a very low ypN+ rate, suggesting the possibility for axillary surgical de-escalation in this subgroup of patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Surgery

Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy

Sanaz Samiei et al.

ANNALS OF SURGERY (2020)

添加到收藏夹

Article Oncology

Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial

Han-Byoel Lee et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

添加到收藏夹

Article Surgery

Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer

Marios Konstantinos Tasoulis et al.

JAMA SURGERY (2020)

添加到收藏夹

Meeting Abstract Oncology

Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery

Mark Basik et al.

CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy

Hee Jun Choi et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

添加到收藏夹

Article Oncology

Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques

Jennifer M. Racz et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer

Zhi-qiang Shi et al.

BREAST JOURNAL (2019)

添加到收藏夹

Article Oncology

Oncotype DXA® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy

Alison M. Pease et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status

Guusje Vugts et al.

BREAST JOURNAL (2018)

添加到收藏夹

Article Surgery

Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy

Alison U. Barron et al.

JAMA SURGERY (2018)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Surgery

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery

Audree B. Tadros et al.

JAMA SURGERY (2017)

添加到收藏夹

Article Surgery

Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Judy C. Boughey et al.

ANNALS OF SURGERY (2017)

添加到收藏夹

Article Oncology

Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study

Jean-Francois Boileau et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar et al.

LANCET (2014)

添加到收藏夹

Article Medicine, General & Internal

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

Judy C. Boughey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Article Oncology

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn et al.

LANCET ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gunter von Minckwitz et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Erik von Elm et al.

LANCET (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.